Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Tours
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed colorectal tumor
first line treatment by a bevacizumab based chemotherapy
Target hepatic metastases of size lower than 5 cm and higher than 5 mm detected by conventional ultrasonography and CT or MRI
Life expectancy \> 2 months
OMS status =\< 2
Major surgery, open biopsy, or significant traumatic injury within 28 days prior to Day 0
informed consent signed
You may not be if
no target hepatic lesion detected by conventional ultrasonography
Prior bevacizumab treatment
Prior chemotherapy treatment for advanced disease
Clinically significant cardiac disease (e.g. myocardial infarction or stroke within 12 months, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure not well controlled with medication, endocarditis and prosthetic valve) and any contraindications in sulphur hexafluoride administration
Blood pressure \>= 180/110 mmHg
Daily and chronic treatment by aspirin or AINS
Anticipation of need for major surgical procedure within 7 days prior day 0
Urine protein \> 1g/24 Hours
Any contraindication in enhancing bevacizumab treatment
Serious, uncontrolled, concurrent infection(s) or illness(es)
pregnant and lactating woman
Clareo Health | Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
